Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$156.38
-0.5%		$174.16
$145.79
▼
$212.71
$243.86B0.263.96 million shs3.70 million shs
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
C$0.09
-10.5%		C$0.08
C$0.03
▼
C$0.10
C$3.24M0.1567,505 shs26,780 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.54
-1.8%		$51.85
$38.63
▼
$61.69
$102.05B0.364.68 million shs3.72 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-0.51%-3.04%-7.06%-13.90%+0.32%
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
0.00%0.00%0.00%0.00%0.00%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-1.83%-6.67%-3.70%-0.24%+26.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$156.38
-0.5%		$174.16
$145.79
▼
$212.71
$243.86B0.263.96 million shs3.70 million shs
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
C$0.09
-10.5%		C$0.08
C$0.03
▼
C$0.10
C$3.24M0.1567,505 shs26,780 shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.54
-1.8%		$51.85
$38.63
▼
$61.69
$102.05B0.364.68 million shs3.72 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-0.51%-3.04%-7.06%-13.90%+0.32%
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
0.00%0.00%0.00%0.00%0.00%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-1.83%-6.67%-3.70%-0.24%+26.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.73
Moderate Buy$211.0034.93% Upside
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
0.00
N/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.10
Hold$53.006.98% Upside

Current Analyst Ratings Breakdown

Latest AZN, BMK, GSK, and DPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
7/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/28/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/24/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral
7/17/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/13/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
7/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
7/6/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeReduce ➝ Hold
7/1/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/1/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
6/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.13$12.86 per share12.16$32.48 per share4.81
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
-C$74K-43.74C$0.01 per share13.00C($0.02) per share-4.25
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.33$5.90 per share8.40$11.40 per share4.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6923.3813.741.3617.02%31.45%13.20%10/30/2026 (Estimated)
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
-C$1.28MN/AN/AN/AN/AN/A-1,679.48%-118.05%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.2015.499.642.8914.56%43.23%11.60%10/28/2026 (Estimated)

Latest AZN, BMK, GSK, and DPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/28/2026Q2 2026 & Strategy update
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.27$1.36+$0.09$0.28$11.02 billion$11.14 billion
7/27/2026Q2 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.50$2.63+$0.13$1.61$15.44 billion$15.38 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.78%+2.30%64.87%N/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/A1.24%N/AN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.793.61%-7.86%55.94%N/A

Latest AZN, BMK, GSK, and DPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45153.65%8/14/20268/14/202610/8/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.47
0.89
0.67
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
3.84
0.10
0.27
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.81
0.82
0.52

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
6.86%
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
MacDonald Mines Exploration Ltd. stock logo
BMK
MacDonald Mines Exploration
238.08 millionN/ANot Optionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable

Recent News About These Companies

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?
August 13 at 7:53 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/could-gsk-plc-gsk-pipeline-220109388.html
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
August 11, 2026  |  cnbc.comhttps://www.cnbc.com/2026/08/11/mmr-vaccine-trump-wants-to-split-childhood-shot-up.html
Parashmoni Deori joins GSK India as Corporate Communications Manager
August 11, 2026  |  exchange4media.comE
GSK slides Monday, underperforms market
August 11, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/gsk-slides-monday-underperforms-market-652d219e-a40c72b56f1e
GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of "Hold" by Brokerages
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943638
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gsk-plc-sponsored-adr-nysegsk-given-average-rating-of-hold-by-brokerages-2026-08-06/
Bernstein Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
August 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/GSK/pressreleases/3630552/bernstein-sticks-to-their-buy-rating-for-glaxosmithkline-gsk/
GSK India first-quarter profit rises on steady vaccine demand
August 3, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/gsk-india-first-quarter-profit-rises-steady-vaccine-demand-2026-08-03/
GSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation Therapeutics
August 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-lse-gsk-opens-cambridge-061535052.html
GSK (NYSE:GSK) Lowered to "Hold" Rating by Wall Street Zen
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gsk-nysegsk-lowered-to-hold-rating-by-wall-street-zen-2026-08-01/
GSK to move R&D to Cambridge in £400m UK investment
July 30, 2026  |  bmmagazine.co.ukB
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
July 30, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/gsk-relation-therapeutics-sign-up-110-million-ai-drug-discovery-deal-2026-07-30/
GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-plc-gsk-q2-2026-010332221.html
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-beats-q2-earnings-revenue-155200606.html
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
July 29, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2963565/gsk-beats-q2-earnings-revenue-estimates-announces-cost-saving-plan?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2963565
GSK PLC Sponsored ADR (NYSE:GSK) Announces Quarterly Dividend of $0.45
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/gsk-plc-sponsored-adr-nysegsk-announces-quarterly-dividend-of-045-2026-07-29/
GSK unveils cost-saving plan to fund R&D, research HQ move
July 28, 2026  |  fiercebiotech.comF
GSK plc (GSK) Q2 2026 Earnings Call Transcript
July 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926597-gsk-plc-gsk-q2-2026-earnings-call-transcript
GSK heads to Cambridge with long-awaited positive vibes
July 28, 2026  |  theguardian.comhttps://www.theguardian.com/business/nils-pratley-on-finance/2026/jul/28/gsk-cambridge-long-awaited-good-vibes
The David Rubenstein Show: GSK CEO Emma Walmsley
July 28, 2026  |  bloomberg.comhttps://www.bloomberg.com/news/videos/2020-11-19/the-david-rubenstein-show-gsk-ceo-emma-walmsley-video
GSK Stock Rises as $2.52 Billion Savings Plan Funds Pipeline
July 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-stock-rises-2-52-195100747.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astrazeneca stock logo

Astrazeneca NYSE:AZN

$156.38 -0.86 (-0.55%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$156.24 -0.14 (-0.09%)
As of 08/14/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

MacDonald Mines Exploration stock logo

MacDonald Mines Exploration CVE:BMK

C$0.08 -0.01 (-10.53%)
As of 05/6/2025

MacDonald Mines Exploration Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company primarily explores for gold, silver, copper, cobalt, and nickel deposits. It owns 100% interests in the Scadding-Powerline-Jovan project that covers an area of 19,455 hectares located in the southeast of the prolific Sudbury Mining Camp in Northern Ontario; and the Hembruff Copper Property, which consists of 30 mining claims that covers an area of 6.64 square kilometers situated in the Elliot Lake, Ontario. The company was formerly known as MacDonald Mines Limited. MacDonald Mines Exploration Ltd. was founded in 1935 and is based in Toronto, Canada.

GSK stock logo

GSK NYSE:GSK

$49.54 -0.91 (-1.80%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$49.53 -0.01 (-0.03%)
As of 08/14/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas